Lucentis therapy is superior to verteporfin photodynamic therapy
Published: 2009-02-16 06:56:00
Updated: 2009-02-16 06:56:00
The 2-year results of the ANCHOR clinical trial indicate that Lucentis therapy for age-related macular degeneration (AMD) with new-onset, predominantly classic choroidal neovascularization (CNV) is superior to verteporfin photodynamic therapy (PDT).
The results were published in an internation...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
